Medicine and device supply issues
This page provides links to information about current supply issues and our instructions to pharmacists.
Benzbromarone (updated 1 May 2020)
Chlorhexidine (HealthE) (updated 6 July 2020)
Clomipramine (added 8 July 2020)
Fluoxetine (updated 28 May 2020)
Gemfibrozil discontinuation (added 25 June 2020)
Labetalol injection (added 17 June 2020)
Levodopa with carbidopa (Sinemet): Resupplied (Updated 20 May 2020)
Montelukast (resolved 16 July 2020)
Morphine sulphate tablets (discontinuation) (updated 13 May 2020)
Paracetamol (updated 16 July 2020 – restrictions remain)
Pfizer stock update (updated salazopyrin 16 July 2020)
Prochlorperazine (Buccastem) (added 27 March 2020)
Propofol (updated 16 July 2020)
Ranitidine (Recall) (updated 9 July 2020)
Suxamethonium (updated 6 July 2020)
About stock issues
When PHARMAC is advised that there may be a shortage of a medicine we take measures to ensure that stock is available to New Zealanders.
Many stock shortages do not result in stock running out; deciding when to publicly notify potential impacts to supply is always a judgement call as it may cause an unnecessary run on stock that will result in negative consequences. We work with Medsafe, DHBs, DHB agents, the Pharmacy Guild and other pharmacy-representative groups when deciding what public notice is required and when.
Last updated: 16 July 2020